Streetbeat News

Price Targets

MBUU

Truist Securities analyst Michael Swartz has maintained a Buy rating on Malibu Boats (NASDAQ:MBUU) but has reduced the price target from $62 to $52, as reported on January 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:09 pm

HCA

Truist Securities analyst David Macdonald has reaffirmed a Buy rating on HCA Healthcare (NYSE:HCA) and increased the price target from $320 to $345.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:07 pm

CORZ

Compass Point analyst Chase White has upgraded Core Scientific (CORZ) from Neutral to Buy and increased the price target from $1 to $8.5.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:02 pm

ZS

Zscaler (NASDAQ:ZS) received mixed ratings from 28 financial analysts, with an average 12-month price target of $215.32, reflecting an 11.47% increase from the previous target. Analysts' actions include maintaining and raising ratings and price targets, indicating a generally positive outlook on the company's performance. Zscaler, a SaaS firm specializing in cloud-native cybersecurity, has shown strong revenue growth but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 7:01 pm

PFE

Pfizer (NYSE:PFE) has received mixed analyst ratings over the past three months, with 8 analysts offering varied opinions. The average 12-month price target is $41.25, up 12.49% from the previous $36.67. Analysts from firms including Cantor Fitzgerald, TD Cowen, Truist Securities, UBS, and Barclays have maintained or lowered their price targets, with ratings ranging from 'Overweight' to 'Neutral'. Pfizer's financials show a revenue decline of -41.55% as of September 30, 2023, a net margin of -18.0%, ROE of -2.43%, ROA of -1.09%, and a debt-to-equity ratio of 0.66.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 7:00 pm

ENVA

Enova International (NYSE:ENVA) has received mixed analyst ratings over the past three months, with 2 somewhat bullish and 2 indifferent ratings. The average 12-month price target for ENVA is $62.75, up from the previous $59.00, with a high estimate of $73.00 and a low of $57.00. Analysts from JMP Securities and BMO Capital have raised their price targets, reflecting a positive outlook on the company's performance. Enova provides online financial services and has shown a revenue growth rate of 20.86% as of September 30, 2023. However, it has a below-industry-average net margin of 7.49% and ROE of 3.29%, but an exceptional ROA of 1.03% and a conservative debt-to-equity ratio of 1.96.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 7:00 pm

MBUU

Analyst ratings for Malibu Boats (NASDAQ:MBUU) show a mix of bullish and somewhat bullish sentiments, with recent price target adjustments reflecting a lower average target of $53.00, down from $57.33. The ratings and targets come from analysts at Raymond James, Keybanc, Baird, and Truist Securities, with actions ranging from maintaining to raising and lowering targets. Malibu Boats is a leading boat manufacturer with a strong market position, but it has faced a revenue decline of -15.35% over the last quarter. Despite this, the company has a high net margin and ROE, indicating strong profitability and financial management.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 7:00 pm

GSHD

Truist Securities analyst Mark Hughes has maintained a Hold rating on Goosehead Insurance (NASDAQ:GSHD) and increased the price target from $65 to $75.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 6:54 pm

CRMD

Truist Securities analyst Joon Lee has maintained a Buy rating on Cormedix (NASDAQ:CRMD) but has reduced the price target from $18 to $14, as reported on January 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 6:43 pm

ZS

JMP Securities analyst Trevor Walsh has maintained a Market Outperform rating on Zscaler (NASDAQ:ZS) and increased the price target from $225 to $270.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 6:41 pm